CYP21A2 Gene Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Genetic Test
Welcome to DNA Labs UAE, where we offer the CYP21A2 Gene Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Genetic Test. This genetic test focuses on analyzing the CYP21A2 gene for mutations associated with adrenal hyperplasia caused by 21-hydroxylase deficiency.
Test Details
The CYP21A2 gene adrenal hyperplasia due to 21-hydroxylase deficiency NGS genetic test is a genetic test that aims to identify mutations in the CYP21A2 gene that may be responsible for adrenal hyperplasia. Adrenal hyperplasia is a group of genetic disorders that affect the adrenal glands, leading to impaired hormone production.
In the case of 21-hydroxylase deficiency, the enzyme responsible for producing cortisol and aldosterone is not functioning properly, resulting in a deficiency of these hormones. The NGS (Next-Generation Sequencing) technology used in this genetic test allows for the simultaneous analysis of multiple genes, including the CYP21A2 gene, to identify mutations or variations that may contribute to the condition.
Test Components and Price
The CYP21A2 Gene Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Genetic Test is priced at AED 4400.0. The test can be performed on blood samples, extracted DNA, or one drop of blood on an FTA card.
Report Delivery
The report for the CYP21A2 Gene Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Genetic Test is typically delivered within 3 to 4 weeks.
Test Type and Department
This genetic test falls under the category of metabolic disorders and is conducted in our Genetics department.
Referring Doctor
The CYP21A2 Gene Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Genetic Test is recommended by General Physicians.
Pre-Test Information
Before undergoing the CYP21A2 Gene Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Genetic Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session may be conducted to draw a pedigree chart of family members affected by adrenal hyperplasia due to 21-hydroxylase deficiency.
Uses and Benefits
The CYP21A2 Gene Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Genetic Test plays a crucial role in diagnosing and managing adrenal hyperplasia. By identifying specific mutations in the CYP21A2 gene, healthcare professionals can confirm a diagnosis and provide appropriate treatment and management options for affected individuals.
This genetic test can also be used for carrier screening in individuals with a family history of adrenal hyperplasia or for prenatal testing in couples at risk of having a child with the condition. Overall, the CYP21A2 Gene Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Genetic Test allows for personalized medical care and informed family planning decisions.
Test Name | CYP21A2 Gene Adrenal hyperplasia due to 21-hydroxylase deficiency Genetic Test |
---|---|
Components | |
Price | 4400.0 AED |
Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
Report Delivery | 3 to 4 Weeks |
Method | NGS Technology |
Test type | Metabolic Disorders |
Doctor | General Physician |
Test Department: | Genetics |
Pre Test Information | Clinical History of Patient who is going for CYP21A2 Gene Adrenal hyperplasia due to 21-hydroxylase deficiency NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with Adrenal hyperplasia due to 21-hydroxylase deficiency |
Test Details |
CYP21A2 gene adrenal hyperplasia due to 21-hydroxylase deficiency NGS genetic test is a genetic test that focuses on analyzing the CYP21A2 gene for mutations associated with adrenal hyperplasia caused by 21-hydroxylase deficiency. Adrenal hyperplasia is a group of genetic disorders that affect the adrenal glands, leading to impaired hormone production. In the case of 21-hydroxylase deficiency, the enzyme responsible for producing cortisol and aldosterone is not functioning properly, leading to a deficiency in these hormones. The NGS (Next-Generation Sequencing) technology used in this genetic test allows for the simultaneous analysis of multiple genes, including the CYP21A2 gene, to identify mutations or variations that may be responsible for the condition. By identifying specific mutations in the CYP21A2 gene, healthcare professionals can confirm a diagnosis of adrenal hyperplasia due to 21-hydroxylase deficiency and provide appropriate treatment and management options for affected individuals. Additionally, this genetic test can also be used for carrier screening in individuals with a family history of the condition or for prenatal testing in couples at risk of having a child with adrenal hyperplasia. Overall, the CYP21A2 gene adrenal hyperplasia due to 21-hydroxylase deficiency NGS genetic test plays a crucial role in diagnosing and managing this genetic disorder, allowing for personalized medical care and informed family planning decisions. |